UPDATE: Barclays Downgrades United Therapeutics Corp. (UTHR) to Underweight
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $513.12 -1.51%
Rating Summary:
17 Buy, 11 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
17 Buy, 11 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
(Updated - November 29, 2016 8:19 AM EST)
Barclays downgraded United Therapeutics Corp. (NASDAQ: UTHR) from Equalweight to Underweight with a price target of $100.00 (from $115.00). Analyst Geoff Meacham said Orenitram uptake will likely be hindered due to Uptravi.
For an analyst ratings summary and ratings history on United Therapeutics Corp. click here. For more ratings news on United Therapeutics Corp. click here.
Shares of United Therapeutics Corp. closed at $132.74 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
- JPMorgan Downgrades Limbach Holdings (LMB) to Underweight
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, DowngradesRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
